Yang Wen Shan, Shi Zhen-Guo, Dong Xian-Zhe, Liu Ping, Chen Meng-Li, Hu Yuan
Department of Pharmacy Medical Supplier Center Chinese PLA General Hospital Beijing China.
Medical School of Chinese PLA Chinese PLA General Hospital Beijing China.
Food Sci Nutr. 2021 Jan 4;9(2):1180-1191. doi: 10.1002/fsn3.2098. eCollection 2021 Feb.
Potential mechanisms of depression involving herbal medicines and their specific compounds include elevated 5-HT level and downstream BDNF pathway. To identify potentially new combined therapeutic strategies, 3,6'-disinapoylsucrose (DISS) and tenuifoliside A (TFSA) have been observed to show antidepressant-like effects and its related 5-HT-BDNF pathway. We have tried to investigate whether combined administration of DISS and TFSA exerted more effective in the treatment of depression, as assessed through tail suspension test (TST) and forced swimming test (FST). In addition, we also analyzed the expression of three important proteins, cyclic adenosine monophosphate (cAMP) response element binding (CREB), brain-derived neurotrophic factor (BDNF), and cAMP-regulated transcriptional coactivators (CRTC1), which have been shown to be involved in the regulation of the neurotrophic factors in the hippocampus. The DISS and TFSA separately, both at a dose of 5 mg/kg each, displayed small effect in the immobility time. However, combined treatment of these two in multiple doses exhibited better effect. Moreover, combined treatment of DISS and TFSA also demonstrated enhanced levels of 5-hydroxytryptamine (5-HT), and stronger increase in the phosphorylation levels of CREB, BDNF, and CRTC1 proteins in the hippocampus. Overall, our results indicated that coadministration of these two oligosaccharide esters at low dose may induce more pronounced antidepressant activity, in comparison with individual treatment even at high dosage. Thus, the antidepressant properties of both these compounds can be attributed to their ability to influence 5-HT and BDNF pathway, and thereby suggesting that this combination strategy can definitely act as alternative therapy for depression disorder with very limited side effects.
涉及草药及其特定化合物的抑郁症潜在机制包括5-羟色胺(5-HT)水平升高和下游脑源性神经营养因子(BDNF)通路。为了确定潜在的新联合治疗策略,已观察到3,6'-二芥子酰蔗糖(DISS)和细叶远志苷A(TFSA)具有抗抑郁样作用及其相关的5-HT-BDNF通路。我们试图研究DISS和TFSA联合给药在治疗抑郁症方面是否更有效,通过悬尾试验(TST)和强迫游泳试验(FST)进行评估。此外,我们还分析了三种重要蛋白质的表达,即环磷酸腺苷(cAMP)反应元件结合蛋白(CREB)、脑源性神经营养因子(BDNF)和cAMP调节的转录共激活因子(CRTC1),这些蛋白质已被证明参与海马体中神经营养因子的调节。DISS和TFSA分别以5mg/kg的剂量单独给药时,对不动时间的影响较小。然而,这两种药物的多剂量联合治疗表现出更好的效果。此外,DISS和TFSA的联合治疗还显示5-羟色胺(5-HT)水平升高,海马体中CREB、BDNF和CRTC1蛋白的磷酸化水平增加更为明显。总体而言,我们的结果表明,与高剂量单独治疗相比,低剂量联合使用这两种寡糖酯可能诱导更显著的抗抑郁活性。因此,这两种化合物的抗抑郁特性可归因于它们影响5-HT和BDNF通路的能力,从而表明这种联合策略肯定可以作为抑郁症的替代疗法,且副作用非常有限。